Successfully selected as a national open topic!

Recently, after evaluation by experts from the Drug Evaluation Center of the National Medical Products Administration, Jiang Ab&B Bio Tech CO., LTD. JS's "Research on Safety Evaluation of Tetravalent Influenza Virus Subunit Vaccines after Market Launch" project has been successfully selected as a national open research topic.

 

 

It is reported that the project was led by Tao Hang, the head of drug vigilance and director of marketing medicine at Ab&B Bio Tech CO., LTD. JS. Under the careful guidance of Jiangsu Province Drug Adverse Reaction Monitoring Center and other units, it was jointly completed by multiple institutions such as Jiangsu Province Drug Adverse Reaction Evaluation Center, Jiangsu Province Center for Disease Control and Prevention, and Nanjing Medical University.

The aim of this project is to evaluate the safety of the quadrivalent influenza virus subunit vaccine in a large-scale population aged 3 and above, and to explore new methods for dynamic monitoring of vaccine safety after market launch. In addition, a large-scale digital information collection method will be used to explore models suitable for China's national conditions for drug surveillance work at the beginning of new drug launch, helping to promote China's vaccine regulatory system towards higher maturity goals.